Literature DB >> 10319156

Selectivity of oxomemazine for the M1 muscarinic receptors.

S W Lee1, C W Woo, J G Kim.   

Abstract

The binding characteristics of pirenzepine and oxomemazine to muscarinic receptor were studied to evaluate the selectivity of oxomemazine for the muscarinic receptor subtypes in rat cerebral microsomes. Equilibrium dissociation constant (KD) of (-)-[3H]quinuclidinyl benzilate([3H]QNB) determined from saturation isotherms was 64 pM. Analysis of the pirenzepine inhibition curve of [3H]QNB binding to cerebral microsome indicated the presence of two receptor subtypes with high (Ki = 16 nM, M1 receptor) and low (Ki = 400 nM, M3 receptor) affinity for pirenzepine. Oxomemazine also identified two receptor subtypes with about 20-fold difference in the affinity for high (Ki = 84 nM, OH receptor) and low (Ki = 1.65 microM, OL receptor) affinity sites. The percentage populations of M1 and M3 receptors to the total receptors were 61:39, and those of OH and OL receptors 39:61, respectively. Both pirenzepine and oxomemazine increased the KD value for [3H]QNB without affecting the binding site concentrations and Hill coefficient for the [3H]QNB binding. Oxomemazine had a 10-fold higher affinity at M1 receptors than at M3 receptors, and pirenzepine a 8-fold higher affinity at OH receptors than at OL receptors. Analysis of the shallow competition binding curves of oxomemazine for M1 receptors and pirenzepine for OL receptors yielded that 69% of M1 receptors were of OH receptors and the remaining 31% of OL receptors, and that 29% of OL receptors were of M1 receptors and 71% of M3 receptors. However, M3 for oxomemazine and OH for pirenzepine were composed of a uniform population. These results suggest that oxomemazine could be classified as a selective drug for M1 receptors and also demonstrate that rat cerebral microsomes contain three different subtypes of M1, M3 and the other site which is different from M1, M2 and M3 receptors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 10319156     DOI: 10.1007/bf02979123

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  34 in total

Review 1.  The molecular basis of muscarinic receptor diversity.

Authors:  T I Bonner
Journal:  Trends Neurosci       Date:  1989-04       Impact factor: 13.837

2.  Distribution of muscarinic receptor subtypes in rat brain as determined in binding studies with AF-DX 116 and pirenzepine.

Authors:  E Giraldo; R Hammer; H Ladinsky
Journal:  Life Sci       Date:  1987-03-02       Impact factor: 5.037

3.  Antagonist discrimination between ganglionic and ileal muscarinic receptors.

Authors:  D A Brown; A Forward; S Marsh
Journal:  Br J Pharmacol       Date:  1980       Impact factor: 8.739

4.  Characterization of muscarinic acetylcholine receptors from mouse brain: evidence for regional heterogeneity and isomerization.

Authors:  Y Kloog; Y Egozi; M Sokolovsky
Journal:  Mol Pharmacol       Date:  1979-05       Impact factor: 4.436

5.  Identification of a family of muscarinic acetylcholine receptor genes.

Authors:  T I Bonner; N J Buckley; A C Young; M R Brann
Journal:  Science       Date:  1987-07-31       Impact factor: 47.728

6.  Competitive interaction of pirenzepine with rat brain muscarinic acetylcholine receptors.

Authors:  E E el-Fakahany; C L Cioffi; M M Abdellatif; M M Miller
Journal:  Eur J Pharmacol       Date:  1986-11-19       Impact factor: 4.432

7.  Comparison of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to muscarinic cholinergic receptors in rat brain.

Authors:  G R Luthin; B B Wolfe
Journal:  J Pharmacol Exp Ther       Date:  1984-03       Impact factor: 4.030

8.  Pirenzepine distinguishes between different subclasses of muscarinic receptors.

Authors:  R Hammer; C P Berrie; N J Birdsall; A S Burgen; E C Hulme
Journal:  Nature       Date:  1980-01-03       Impact factor: 49.962

9.  Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells.

Authors:  C Bolden; B Cusack; E Richelson
Journal:  J Pharmacol Exp Ther       Date:  1992-02       Impact factor: 4.030

10.  Antagonist binding profiles of five cloned human muscarinic receptor subtypes.

Authors:  F Dörje; J Wess; G Lambrecht; R Tacke; E Mutschler; M R Brann
Journal:  J Pharmacol Exp Ther       Date:  1991-02       Impact factor: 4.030

View more
  2 in total

1.  M3 muscarinic receptor in the ventral medial prefrontal cortex modulating the expression of contextual fear conditioning in rats.

Authors:  A G Fedoce; N C Ferreira-Junior; D G Reis; F M A Corrêa; L B M Resstel
Journal:  Psychopharmacology (Berl)       Date:  2015-10-31       Impact factor: 4.530

2.  Involvement of M1 and CB₁ receptors in the anxiogenic-like effects induced by neostigmine injected into the rat prelimbic medial prefrontal cortex.

Authors:  M V Fogaça; A G Fedoce; N C Ferreira-Junior; F S Guimarães; L B Resstel
Journal:  Psychopharmacology (Berl)       Date:  2016-02-13       Impact factor: 4.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.